BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Mary Anne Heino, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference at 11:15 a.m. PST on Wednesday, January 10.
To access a live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcast will be available on the Company’s website for at least 30 days following the live presentation.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
This email address is being protected from spambots. You need JavaScript enabled to view it.
Melissa Downs
Senior Director, External Communications
646-975-2533
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$86.45 |
Daily Change: | 7.02 8.84 |
Daily Volume: | 2,006,834 |
Market Cap: | US$6.000B |
November 13, 2024 November 06, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB